EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics

PHASE4RecruitingINTERVENTIONAL
Enrollment

1,900

Participants

Timeline

Start Date

December 12, 2023

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2026

Conditions
Blood Stream InfectionsVentilator Associated PneumoniaHealthcare Associated InfectionCarbapenem-Resistant Enterobacteriaceae InfectionHospital-acquired Pneumonia
Interventions
DIAGNOSTIC_TEST

Rapid Diagnostics

Patients randomised to the intervention arm, will have the BioFire Blood Culture Identification 2 Panel (BCID2) used for positive blood cultures and/or the BioFire FilmArray Pneumonia plus PanelPneumonia Panel or Pneumonia plus Panel for respiratory tract specimens if having hospital-acquired pneumonia or ventilator-associated pneumonia. Standard of care diagnostics will also be used. Antibiotic guidelines will be provided to clinicians to aid interpretation of test results and treatment prescription. Ceftazidime-avibactam will be available for targeted use in patients with Pseudomonas aeruginosa or carbapenemase producing Enterobacterales.

Trial Locations (4)

1650

RECRUITING

Taichung Veterans General Hospital, Taichung

34000

NOT_YET_RECRUITING

Sunpasitthiprasong Hospital, Ubon Ratchathani

50603

NOT_YET_RECRUITING

University Malaya Medical Centre, Kuala Lumpur

Unknown

NOT_YET_RECRUITING

Kaohsiung Medical University Hospital, Kaohsiung City

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

Biomerieux inc

INDUSTRY

lead

National University of Singapore

OTHER

NCT05979545 - EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics | Biotech Hunter | Biotech Hunter